PNAS QnAs with NAS member and chemist Shaul Mukamel.
New Research In
Physical Sciences
Featured Portals
Articles by Topic
Biological Sciences
Featured Portals
Articles by Topic
Edited* by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved May 19, 2011 (received for review December 29, 2010)
Abstract
Serum levels of apolipoprotein CIII (apoCIII) are increased in type 1 diabetic patients, and when β cells are exposed to these diabetic sera, apoptosis occurs, an effect abolished by an antibody against apoCIII. We have investigated the BB rat, an animal model that develops a human-like type 1 diabetes, and found that apoCIII was also increased in sera from prediabetic rats. This increase in apoCIII promoted β-cell death. The endogenous levels of apoCIII were reduced by treating prediabetic animals with an antisense against this apolipoprotein, resulting in a significantly delayed onset of diabetes. ApoCIII thus serves as a diabetogenic factor, and intervention with this apolipoprotein in the prediabetic state can arrest disease progression. These findings suggest apoCIII as a target for the treatment of type 1 diabetes.
Footnotes
- ↵1To whom correspondence should be addressed. E-mail: lisa.juntti-berggren{at}ki.se.
Author contributions: R.H., P.-O.B., and L.J.-B. designed research; R.H., E.R., and L.J.-B. performed research; R.M.C., M.G., and G.O. contributed new reagents/analytic tools; R.H., E.R., A.H., and L.J.-B. analyzed data; and P.-O.B. L.J.-B. wrote the paper.
Conflict of interest statement: P.-O.B. is a co-founder of Biocrine, a company that is developing apoCIII as a target for the treatment of type 1 diabetes and its complications. R.M.C. and M.G. are affiliated with ISIS, a company whose main focus is to develop antisense treatment strategies for various diseases.
↵*This Direct Submission article had a prearranged editor.
Lowering apolipoprotein CIII delays onset of type 1 diabetes
More Articles of This Classification
Biological Sciences
Medical Sciences
Related Content
Cited by...
- Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
- Apolipoprotein CIII links islet insulin resistance to {beta}-cell failure in diabetes
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Similar Articles
You May Also be Interested in
Researchers report links between warming and predator-prey interactions in the Arctic and suggest that predator activity can influence carbon and nitrogen dynamics in the Arctic, but that warming may alter or reverse such effects.
Image courtesy of Modman/Pixabay.
A study finds that individuals with major depressive disorder had lower blood levels of acetyl-L-carnitine (LAC) than healthy controls, suggesting that LAC might aid the diagnosis of severe, trauma-associated depression.
Image courtesy of PublicDomainPictures/Pixabay.
A study explores historical fire activity associated with bison hunting by indigenous groups in North America, and suggests that fire use by indigenous hunters might have amplified the effect of climate variability on fire activity in the North American Great Plains.
Lauren Schiebelhut describes natural selection following sea star wasting disease.
